This study examines Still’s disease, a rare inflammatory condition that causes fever, rash, and joint pain. The condition can affect both children and adults, and it involves inflammation throughout the body that can lead to various symptoms including swelling of the joints and organs. The study will test a medicine called MAS825, which is a laboratory-made protein designed to block certain substances in the body that cause inflammation. Participants will also receive glucocorticoids, which are medications commonly used to reduce inflammation and are part of the standard treatment for this condition. The purpose of the study is to see how well MAS825 works in reducing disease activity in people with Still’s disease.
During the study, participants will receive MAS825 through an injection into a vein, under the skin, or into a muscle, along with their glucocorticoid treatment. The study will look at whether the treatment helps control the disease and whether it allows participants to reduce the amount of glucocorticoids they need to take. The treatment period can last for several years, during which participants will be monitored regularly to check how they are responding to the medicine.
Throughout the study, doctors will assess various aspects of the participants’ health, including changes in disease activity, physical function, and any side effects that may occur. Safety will be monitored through regular checks of vital signs, heart function using an ECG, and blood tests. The study will also track whether participants experience any unwanted effects from the treatment and whether the disease becomes inactive while taking lower doses of glucocorticoids.
France 
Germany 
Italy 
Spain 
The Netherlands 
